www.public4you.fora.pl

ausc8qld5bm

Drugs as China declared a non-independent countries, imported drugs need to have reference to State approval to declare the import. Europe and the United States and other developed countries over the past listed drugs are generally 7-8 years in order to enter the Chinese market, and some even longer.
Scleroderma interferon, by the end of the re-introduction of human insulin and forest. The next five years, is expected to have 20 new products into China.
It is understood that Bayer is expected in the Chinese market for the new product portfolio [link widoczny dla zalogowanych], including cancer, heart failure [link widoczny dla zalogowanych], breast cancer, and other products will be available in August this year, for multiple
Now Bayer Schering Pharma new drug approval process is expected to be reduced to 1 year or less.

In the past 10 years, the rapid development of Chinese economy and China's urbanization rate is the basis for Bayer to increase the growth rate of about one-fifth of cardiovascular disease deaths occur in China. The proportion of cancer deaths in China are similar. Currently, about 30 million people died of liver cancer each year in the United States, 24 are,
Bayer Schering Pharma was established in Beijing in 2009, global R & D center, the purpose is to accelerate the introduction of new drugs for the local market and increase market penetration.

According to McKinsey (McKinsey) predicted that by 2020 more than 50 years old and 50-year-old population will reach 5 billion yuan.

Bayer Schering Pharma China / Hong Kong Island and the Chinese president Li Xilie Bayer HealthCare, said: "Given China's pharmaceutical market growth rate of 20% per year, Bayer expects the Chinese market contribution to global business in 2013 to 29%. "current contribution rate of about 10%.
2009, Bayer Schering Pharma R & D centers in China, and Shanghai Institute of Organic Chemistry, Tsinghua University and other cooperation, through local experts in biological sciences and chemical R & D, to its product line [link widoczny dla zalogowanych], and tumors, women health, cardiology and other diagnostic imaging and is focused on areas of cooperation.
Lifestyle changes also will increase health care demand, China has 30 million diabetics, and the smoking population worldwide 1 / 3.

Bayer is currently in China, one of the top three foreign pharmaceutical companies, diabetes care, cardiovascular disease treatment business in a leading position. In 2009, the company's sales in China 530 million euros, an increase of 28%. An increase of more than four years ago, 7 times. Only one of which is approved for use pre-diabetes drug Acarbose treatment of oral hypoglycemic sales last year rose 28% to 143 million euros. Other cardiovascular medications Adalat 39% of sales in 2009, 1.01 billion euros.

This can not only use Bayer and local hospitals and research institutions "integrated" network of researchers, so that more Chinese patients were involved in early clinical trials, but also so that more medical research and development outsourcing (CRO) more frequent cooperation eventually speed up the approval process for new drugs in China, and the market.
According to Bayer Schering Pharma China, Wang Min, director of medical department of introduction, this "integrated development" strategy is characterized by the largest clinical activities so that more can be carried out in China. "2010, due to the establishment of independent regional structure, Bayer R & D center in China to carry out clinical trials has increased significantly. From 2005 to three
Chemical Network News, 27 April, the German pharmaceutical group Bayer subsidiary Bayer Schering Pharma announced that 2010 will be published in the Chinese market four drugs. Continues to accelerate the advance in the Chinese market and invest in the next 5 years, 100 million euros for the development of new drugs for the Chinese market.